Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,325 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,671 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04223999 | Improving Tumor Treating Fields Treatment for Brain Cancer Patients With Skullremodeling Surgery (Neurosurgery)(OptimalTTF-2) | unknown | Phase 2 | 70 | Anders Rosendal KorshøjOTHER | 1 | Jun 6, 2023 | clinicaltrials |
| NCT03077828 | Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma | unknown | Phase 2 | 43 | Northwestern UniversityOTHER | 1 | Jun 2, 2023 |
| clinicaltrials |
| NCT03226249 | PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma | unknown | Phase 2 | 30 | Northwestern UniversityOTHER | 1 | Jun 2, 2023 | clinicaltrials |
| NCT03568097 | Immunotherapy in Combination With Chemotherapy in Small-cell Lung Cancer(PAVE) | unknown | Phase 2 | 55 | Hellenic Cooperative Oncology GroupOTHER | 1 | Jun 2, 2023 | clinicaltrials |
| NCT05886465 | HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 Trial | unknown | Phase 2 | 40 | Sun Yat-sen UniversityOTHER | 1 | Jun 2, 2023 | clinicaltrials |
| NCT03567720 | Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC | unknown | Phase 2 | 65 | OncoSec Medical IncorporatedINDUSTRY | 2 | Jun 1, 2023 | clinicaltrials |
| NCT04631731 | Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity(ICEMELT) | unknown | Phase 1 / Phase 2 | 200 | Western Sydney Local Health DistrictOTHER | 1 | Jun 1, 2023 | clinicaltrials |
| NCT05498389 | EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer | unknown | Phase 1 / Phase 2 | 115 | Shanghai EpimAb Biotherapeutics Co., Ltd.INDUSTRY | 2 | Jun 1, 2023 | clinicaltrials |
| NCT03797391 | A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors | unknown | Phase 1 / Phase 2 | 186 | Shanghai EpimAb Biotherapeutics Co., Ltd.INDUSTRY | 2 | May 31, 2023 | clinicaltrials |
| NCT05233332 | Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC)(mCRC) | unknown | Phase 2 | 186 | Shanghai Kechow Pharma, Inc.INDUSTRY | 1 | May 31, 2023 | clinicaltrials |
| NCT05263453 | HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation | unknown | Phase 2 | 104 | Shanghai Kechow Pharma, Inc.INDUSTRY | 1 | May 31, 2023 | clinicaltrials |
| NCT05882630 | Surufatinib Combined With Serplulimab Plus Chemotherapy in the Treatment of Extensive-stage Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 39 | Fujian Cancer HospitalOTHER_GOV | 1 | May 31, 2023 | clinicaltrials |
| NCT05883176 | TACE Combined With Bevacizumab in HCC (BCLC-B) Beyond Up-To-Seven Criteria(B-TACE) | unknown | Phase 2 | 35 | Sun Yat-sen UniversityOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT02687958 | Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin | unknown | Phase 2 | 30 | Gruppo Oncologico Italiano di Ricerca ClinicaOTHER | 1 | May 30, 2023 | clinicaltrials |
| NCT05823246 | Safety and Efficacy Study of QLF31907 in Advanced Melanoma and Urothelial Carcinoma | unknown | Phase 2 | 66 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 26, 2023 | clinicaltrials |
| NCT05877911 | Effect of Sodium Thiosulfate on Nephrotoxicity of Cisplatin Intraperitoneal Heat-perfusion Chemotherapy | unknown | Phase 2 | 110 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | May 26, 2023 | clinicaltrials |
| NCT05799820 | QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC | unknown | Phase 2 | 60 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 25, 2023 | clinicaltrials |
| NCT05872412 | Effect of Platinum-based Versus Non-platinum-based Neoadjuvant Chemotherapy in Triple-negative Breast Cancer | unknown | Phase 2 | 82 | Bangabandhu Sheikh Mujib Medical University, Dhaka, BangladeshOTHER | 1 | May 25, 2023 | clinicaltrials |
| NCT05874778 | A Multicenter, Phase 2 Study Evaluating the Value of Radiotherapy in Advanced Diffuse Large B-cell Lymphoma Patients With Extranodal Involvement and Large Tumors Undergoing Immunochemotherapy for PET-CT Assessment of Complete Remission | unknown | Phase 2 | 108 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | May 25, 2023 | clinicaltrials |
| NCT03820310 | Clinical Trial of Autologous Tcm Immunotherapy in ICC | unknown | Phase 2 | 20 | Newish Technology (Beijing) Co., Ltd.INDUSTRY | 1 | May 24, 2023 | clinicaltrials |
| NCT05140811 | A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome | unknown | Phase 1 / Phase 2 | 126 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 1 | May 24, 2023 | clinicaltrials |
| NCT05771883 | A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide | unknown | Phase 1 / Phase 2 | 102 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 0 | May 24, 2023 | clinicaltrials |
| NCT05872841 | H101 Combined With TACE for Primary Hepatocellular Carcinoma With Portal Vein Thrombosis | unknown | Phase 2 | 38 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | May 24, 2023 | clinicaltrials |
| NCT04923048 | A Safety, Tolerability, Pharmacokinetics and Efficacy Study of GB261 in B-Cell NHL and CLL. | unknown | Phase 1 / Phase 2 | 460 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | May 22, 2023 | clinicaltrials |
| NCT04580498 | A Trial of SHR-1701 With or Without Chemotherapy in Patients With Stage III NSCLC | unknown | Phase 2 | 107 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | May 19, 2023 | clinicaltrials |
| NCT05858814 | RC1012 Injection (Allo-DNT Cells) for the Prevention of Relapse in AML Patients After Allo-HSCT | unknown | Phase 1 / Phase 2 | 72 | Guangdong Ruishun Biotech Co., LtdINDUSTRY | 1 | May 19, 2023 | clinicaltrials |
| NCT05865730 | A Study of Oncobax®-AK in Patients With Advanced Solid Tumors | unknown | Phase 2 | 122 | EverImmuneINDUSTRY | 2 | May 19, 2023 | clinicaltrials |
| NCT05038813 | Anlotinib Combined With TQB2450 (PD-L1 Inhibitor) in the Treatment of Advanced Esophageal Squamous Cell Carcinoma(ESCC) | unknown | Phase 2 | 46 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | May 18, 2023 | clinicaltrials |
| NCT05763992 | Targeting Triple Negative BREAst Cancer Metabolism With a Combination of Chemoimmunotherapy and a FASTing-like Approach in the Preoperative Setting: the BREAKFAST 2 Trial(BREAKFAST-2) | unknown | Phase 2 | 145 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | May 18, 2023 | clinicaltrials |
| NCT05865132 | Palbociclib Combined With Afatinib for Advanced Squamous Carcinoma of Esophagus or Gastroesophageal Junction | unknown | Phase 2 | 30 | AIPING ZHOUOTHER | 1 | May 18, 2023 | clinicaltrials |
| NCT05861557 | Neoadjuvant Radiotherapy Combined With Toripalimab for Locally Advanced Head and Neck Squamous Cell Carcinoma | unknown | Phase 2 | 23 | Tianjin Medical University General HospitalOTHER | 1 | May 17, 2023 | clinicaltrials |
| NCT05859373 | To Evaluate the Efficacy and Safety of TQB3728 Tablets in Sequential Maintenance of TQB2450 Injection Therapy in Patients After Sequential or Concurrent Chemoradiation for Locally Advanced Non-small Cell Lung Cancer. | unknown | Phase 1 / Phase 2 | 78 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 16, 2023 | clinicaltrials |
| NCT05857982 | Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed/Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 20 | Second Affiliated Hospital of Soochow UniversityOTHER | 1 | May 15, 2023 | clinicaltrials |
| NCT04940637 | UNITO-001- Study in HRR/PDL1 Positive MPM/NSCLC(UNITO-001) | unknown | Phase 2 | 70 | University of Turin, ItalyOTHER | 1 | May 12, 2023 | clinicaltrials |
| NCT05854589 | Effect of Topical Application of Hypertonic Saline on Melanoma on Its Sizes and Number. | unknown | Phase 2 | 20 | Rafik BatroussyOTHER | 0 | May 11, 2023 | clinicaltrials |
| NCT04202809 | Phase-II Trial of Induction Chemotherapy and Chemoradiotherapy Plus/Minus Durvalumab and Consolidation Immunotherapy in Patients With Resectable Stage III NSCLC.(ESPADURVA) | unknown | Phase 2 | 90 | University Hospital, EssenOTHER | 1 | May 10, 2023 | clinicaltrials |
| NCT02632396 | Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in Remission | unknown | Phase 1 / Phase 2 | 12 | Emory UniversityOTHER | 1 | May 9, 2023 | clinicaltrials |
| NCT05816746 | Decitabine and Anti-PD-1 in R/R DLBCL | unknown | Phase 2 | 20 | Chinese PLA General HospitalOTHER | 1 | May 9, 2023 | clinicaltrials |
| NCT05821738 | Avapritinib in CBF-AML With KIT Mutations | unknown | Phase 2 | 50 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | May 9, 2023 | clinicaltrials |
| NCT05847764 | Disitamab Vedotin Combined Therapy for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations | unknown | Phase 2 | 95 | Sun Yat-sen UniversityOTHER | 1 | May 8, 2023 | clinicaltrials |
| NCT02137759 | MRSI to Predict Response to RT/TMZ ± Belinostat in GBM | unknown | Phase 2 | 29 | Emory UniversityOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT04586088 | Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure | unknown | Phase 2 | 58 | Sun Yat-sen UniversityOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT05252403 | Residual Disease Driven Strategy for CARCIK (CD19) in Adults/Pediatric BCP-ALL | unknown | Phase 2 | 35 | Fondazione Matilde Tettamanti Menotti De Marchi OnlusOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT04542369 | Pilot Study of PD-1inhibitor (Tislelizumab) Plus Chemotherapy as Neoadjuvant Therapy for Limited-Stage Small-Cell Lung Cancer | unknown | Phase 2 | 15 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT03534050 | Neuropsychological and Oncological Outcomes in Grade 2 or 3 Glioma Patients Undergoing Postoperative Modern Radiotherapy | unknown | Phase 2 / Phase 3 | 80 | Chang Gung Memorial HospitalOTHER | 1 | May 1, 2023 | clinicaltrials |
| NCT05723432 | KD6001 in Combination With Anti-PD-1 Antibody in Patients With Advanced Melanoma | unknown | Phase 1 / Phase 2 | 84 | Shanghai Kanda Biotechnology Co., Ltd.INDUSTRY | 1 | Apr 27, 2023 | clinicaltrials |
| NCT05833971 | Cadonilimab in Combination With Chemotherapy for Locally Advaced Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 43 | Guangzhou Institute of Respiratory DiseaseOTHER | 0 | Apr 27, 2023 | clinicaltrials |
| NCT05833984 | Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas | unknown | Phase 1 / Phase 2 | 309 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 1 | Apr 27, 2023 | clinicaltrials |
| NCT05134532 | Regorafenib After Progression on Atezolizumab Plus Bevacizumab in Advanced HCC(HCC) | unknown | Phase 2 | 40 | CHA UniversityOTHER | 1 | Apr 26, 2023 | clinicaltrials |
| NCT05827770 | The Efficacy and Safety of Neoadjuvant Toripalimab Combined With Temozolomide in Resectable Stage III Melanoma | unknown | Phase 2 | 20 | Yong ChenOTHER | 1 | Apr 25, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Jun 6, 2023source: clinicaltrials